289 related articles for article (PubMed ID: 21107288)
1. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
Reinersman JM; Johnson ML; Riely GJ; Chitale DA; Nicastri AD; Soff GA; Schwartz AG; Sima CS; Ayalew G; Lau C; Zakowski MF; Rusch VW; Ladanyi M; Kris MG
J Thorac Oncol; 2011 Jan; 6(1):28-31. PubMed ID: 21107288
[TBL] [Abstract][Full Text] [Related]
2. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
3. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.
Cote ML; Haddad R; Edwards DJ; Atikukke G; Gadgeel S; Soubani AO; Lonardo F; Bepler G; Schwartz AG; Ethier SP
J Thorac Oncol; 2011 Mar; 6(3):627-30. PubMed ID: 21317742
[TBL] [Abstract][Full Text] [Related]
4. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
5. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Leidner RS; Fu P; Clifford B; Hamdan A; Jin C; Eisenberg R; Boggon TJ; Skokan M; Franklin WA; Cappuzzo F; Hirsch FR; Varella-Garcia M; Halmos B
J Clin Oncol; 2009 Nov; 27(33):5620-6. PubMed ID: 19786660
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
Gao J; Chen JQ; Zhang L; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
[TBL] [Abstract][Full Text] [Related]
7. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
8. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
10. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
12. Genotyping non-small cell lung cancer (NSCLC) in Latin America.
Arrieta O; Cardona AF; Federico Bramuglia G; Gallo A; Campos-Parra AD; Serrano S; Castro M; Avilés A; Amorin E; Kirchuk R; Cuello M; Borbolla J; Riemersma O; Becerra H; Rosell R;
J Thorac Oncol; 2011 Nov; 6(11):1955-9. PubMed ID: 22005474
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
[TBL] [Abstract][Full Text] [Related]
14. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
15. EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.
Bircan S; Baloglu H; Kucukodaci Z; Bircan A
Med Oncol; 2014 Aug; 31(8):87. PubMed ID: 24973952
[TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.
Bacchi CE; Ciol H; Queiroga EM; Benine LC; Silva LH; Ojopi EB
Clinics (Sao Paulo); 2012; 67(5):419-24. PubMed ID: 22666783
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
[TBL] [Abstract][Full Text] [Related]
20. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.
Lewandowska MA; Jóźwicki W; Jochymski C; Kowalewski J
Oncol Rep; 2013 Sep; 30(3):1045-52. PubMed ID: 23817662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
